Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon May 20, 2018 12:35pm
160 Views
Post# 28058137

RE:RE:RE:RE:RE:Echelon Partners

RE:RE:RE:RE:RE:Echelon Partners
Yes, I am likely being too conservative.

The first few weeks may have been something like 20,40,60 scripts in weeks 1-3.

Now, with insurance coming on board and 250 clinics looking in to the drug, we should see further acceleration. Therefore, we could see a big jump in scripts written.

The funny things is if they report 1000 pts, that is around an EPS of 68 cents per share for these pts over a 12 month period (factoring out Egrifta paying for expenses).

That would make the current share price still a joke as at a minimum, a PE of 40 would need to be considered with this growth rate.

Meanwhile, it looks like Europe has the possibility of adding $8-10 or so to the SP down the line.

This could be a rather interesting summer for TH’s share price if the pace of script keeps accelerating.

bfw





palinc2000 wrote: Accelarating I think (I hope)should mean more than 500!
One thousand or there about with ignite the SP


Bullboard Posts